Navigation Links
AEterna's acquisition of Zentaris being followed up with its new product pipeline and clinical development strategy

AEterna Laboratories Inc., a biopharmaceutical company focused on the development of novel therapeutic treatments in oncology and endocrinology recently acquired the new German based biopharmaceutical company, Zentaris AG. Following this acquisition// the new entity has in the pipeline six clinical stage products and two preclinical stage products, in oncology and one product already approved and marketed for in vitro fertilization in endocrinology. There are also two products in the preclinical stage and one in the clinical stage, in endocrinology.

AEterna's Chairman and CEO, Dr. Eric Dupont, believes that they now have the right partner to develop a leadership position in two growing therapeutic areas, oncology and endocrinology as Zentaris provides experienced management and drug development teams, an already marketed product, a solid financial position with a positive cash flow for 2002, eight additional global pharmaceutical partnerships and an impressive drug discovery platform.

AEterna's and Zentaris' combined clinical development strategy is based on five factors; development costs, competitive environment, involvement of pharmaceutical partners, time to market and potential markets for future drugs. The new structure is expected to drive drug discovery on an ongoing- forward basis through a state-of-the-art drug discovery unit, including a 100,000 proprietary compound library. Gilles Gagnon, President and COO at AEterna added that given the above five factors and and a portfolio of 12 products in development, the strategy for Neovastat will now strictly focus on the two ongoing Phase III studies in kidney cancer and lung cancer. Results of the kidney cancer trial are expected by the first or second quarter of 2003, while those of the lung cancer trial should be disclosed by the end of 2005.

Prof. Dr. Jurgen Engel, Chief Executive Officer at Zentaris concluded that the combined expertise will allow advancement of multiple pro mising preclinical and clinical projects for the development of novel treatments focused on oncology and endocrinology.


'"/>




Related medicine news :

1. NHS financial crisis may lead to roll back of flexi-work scheme and private acquisition
2. Are cancer patients being taken for a ride?
3. Nervous disorder being treated
4. Benign eye tumors being treated
5. Heart disease in women being under-treated
6. Chance of water births being urged for mums-to-be
7. CPR! How Effectively is it being done ?
8. Men tend to deny being overweight
9. Yoga, ayurveda being documented to stop patent misuse
10. Surgeons being paid triple the amount to cut waiting lists
11. Fund being raised for treatment to HIV positive Libyan kid
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:6/25/2016)... ... 25, 2016 , ... Conventional wisdom preaches the benefits of moderation, whether it’s ... setting the bar too high can result in disappointment, perhaps even self-loathing. However, those ... goal. , Research from PsychTests.com reveals that behind the tendency to ...
(Date:6/24/2016)... ... June 24, 2016 , ... Marcy was in a crisis. Her son James, eight, was out ... family verbally and physically. , “When something upset him, he couldn’t control his emotions,” remembers ... would throw rocks at my other children and say he was going to kill them. ...
(Date:6/24/2016)... ... June 24, 2016 , ... Comfort Keepers® of San ... Society and the Road To Recovery® program to drive cancer patients to and from ... adults to ensure the highest quality of life and ongoing independence. Getting to ...
(Date:6/24/2016)... New York, NY (PRWEB) , ... June 24, ... ... lifestyle publication Haute Living, is proud to recognize Dr. Barry M. Weintraub as ... believes that “the most beautiful women in the world, and the most handsome ...
(Date:6/24/2016)... ... ... Venture Construction Group (VCG) sponsors Luke’s Wings 5th Annual ... Country Club at 1201 Rockville Pike, Rockville, Maryland, 20852. The event raised funds ... been wounded in battle and their families. Venture Construction Group is a 2016 Silver ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... June 23, 2016 Research and ... Excipients Market by Type (Organic Chemical (Sugar, Petrochemical, Glycerin), ... Topical, Coating, Parenteral) - Global Forecast to 2021" ... The global pharmaceutical excipients market is projected ... CAGR of 6.1% in the forecast period 2016 to ...
(Date:6/23/2016)... DUBLIN , June 23, 2016 ... "Global MEMS Devices Medical Market Analysis 2016 - Forecast to ... The report contains up to date financial ... reliable analysis. Assessment of major trends with potential impact on ... dive analysis of market segmentation which comprises of sub markets, ...
(Date:6/23/2016)... 2016 Bracket , a leading clinical trial ... clinical outcomes platform, Bracket eCOA (SM) 6.0, at the ... – 30, 2016 in Philadelphia , Pennsylvania.  ... Assessment product of its kind to fully integrate with RTSM, ... eCOA 6.0 is a flexible platform for electronic clinical outcomes ...
Breaking Medicine Technology: